Multimarker approach for identifying and documenting mitigation of cardiovascular risk

Future Cardiology

Volumn 9, Issue 4, 2013, Pages 497-506

  Penn, Marc S ^a,b   Klemes, Andrea B ^c  

^a Cleveland Heart Lab   (United States)

^b SUMMA HEALTH SYSTEM   (United States)

^c MDVIP Inc   (United States)

Author keywords

Cardiovascular risk; Diabetes; Hyperlipidemia; Inflammation

Indexed keywords

BIOLOGICAL MARKER; COLLAGEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN 2; HIGH DENSITY LIPOPROTEIN 3; ISOPROSTANE DERIVATIVE; LOW DENSITY LIPOPROTEIN; MYELOPEROXIDASE; OXIDIZED LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ACUTE CORONARY SYNDROME; ATHEROSCLEROTIC PLAQUE; C REACTIVE PROTEIN TEST KIT; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; COST; HUMAN; MACROPHAGE ACTIVATION; MICROALBUMINURIA; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SCREENING; WELLBEING;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; HUMANS; INCIDENCE; PREVALENCE; PROGNOSIS; RISK ASSESSMENT; WORLD HEALTH;

EID: 84880351777     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.13.27     Document Type: Review

References (23)

1. Siegel RL, Ward EM, Jemal A. Trends in colorectal cancer incidence rates in the United States by tumor location and stage, 1992-2008. Cancer Epidemiol. Biomarkers. Prev. 21(3), 411-416 (2012).
2. McManus DD, Gore J, Yarzebski J, Spencer F, Lessard D, Goldberg RJ. Recent trends in the incidence, treatment, and outcomes of patients with STEMI and NSTEMI. Am. J. Med. 124(1), 40-47 (2011).
3. Agarwal U, Zhou X, Weber K, Dadabayev AR, Penn MS. Critical role for white blood cell NAD(P)H oxidase-mediated plasminogen activator inhibitor-1 oxidation and ventricular rupture following acute myocardial infarction. J. Mol. Cell. Cardiol. 50, 426-432 (2011).
4. Kerekes G, Soltesz P, Nurmohamed MT et al. Validated methods for assessment of subclinical atherosclerosis in rheumatology. Nat. Rev. Rheumatol. 8(4), 224-234 (2012).
5. Brennan ML, Penn MS, Van Lente F et al. Prognostic value of myeloperoxidase in patients with chest pain. N. Engl. J. Med. 349(17), 1595-1604 (2003). (Pubitemid 37288567)
6. Salonen JT, Salonen R, Seppanen K, Rauramaa R, Tuomilehto J. HDL, HDL2, and HDL3 subfractions, and the risk of acute myocardial infarction. A prospective population study in eastern Finnish men. Circulation 84(1), 129-139 (1991).
7. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N. Engl. J. Med. 347(20), 1557-1565 (2002). (Pubitemid 35315836)
8. Ridker PM, Cannon CP, Morrow D et al. C-reactive protein levels and outcomes after statin therapy. N. Engl. J. Med. 352(1), 20-28 (2005). (Pubitemid 40075677)
9. Ridker PM, Danielson E, Fonseca FA et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359(21), 2195-2207 (2008).
10. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 105(9), 1135-1143 (2002). (Pubitemid 34212626)
11. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N. Engl. J. Med. 336(14), 973-979 (1997). (Pubitemid 27152782)
12. Pedersen TR, Kjekshus J, Berg K et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 344(8934), 1383-1389 (1994). (Pubitemid 24365311)
13. Roest M, Voorbij HA, Van Der Schouw YT, Peeters PH, Teerlink T, Scheffer PG. High levels of urinary F2-isoprostanes predict cardiovascular mortality in postmenopausal women. J. Clin. Lipidol. 2(4), 298-303 (2008
14. Siamakpour-Reihani S, Scarbrough PM, Wang F et al. Systemic markers of oxidative status and colorectal adenomatous polyps. Ann. Epidemiol. 22(8), 587-591 (2012).
15. Holvoet P, Lee DH, Steffes M, Gross M, Jacobs DR Jr. Association between circulating oxidized low-density lipoprotein and incidence of the metabolic syndrome. JAMA 299(19), 2287-2293 (2008). (Pubitemid 351724395)
16. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators; N. Engl. J. Med. 342(3), 145-153 (2000); erratum in N. Engl. J. Med. 342(10), 748 (2000); N. Engl. J. Med. 342(18), 1376 (2000).
17. Kolodgie FD, Burke AP, Skorija KS et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 26(11), 2523-2529 (2006). (Pubitemid 44607475)
18. Penn MS. The role of leukocyte-generated oxidants in left ventricular remodeling. Am. J. Cardiol. 101(10A), D30-D33 (2008).
19. Oemrawsingh RM, Lenderink T, Akkerhuis KM et al. Multimarker risk model containing troponin-T, interleukin 10, myeloperoxidase and placental growth factor predicts long-term cardiovascular risk after non-ST-segment elevation acute coronary syndrome. Heart 97(13), 1061-1066 (2011).
20. Heslop CL, Frohlich JJ, Hill JS. Myeloperoxidase and C-reactive protein have combined utility for long-term prediction of cardiovascular mortality after coronary angiography. J. Am. Coll. Cardiol. 55(11), 1102-1109 (2010).
21. Wong ND, Gransar H, Narula J et al. Myeloperoxidase, subclinical atherosclerosis, and cardiovascular disease events. JACC Cardiovasc. Imaging 2(9), 1093-1099 (2009).
22. Brevetti G, Schiano V, Laurenzano E et al. Myeloperoxidase, but not C-reactive protein, predicts cardiovascular risk in peripheral arterial disease. Eur. Heart J. 29(2), 224-230 (2008). (Pubitemid 351164877)
23. Matusiak N, van Waarde A, Bischoff R et al. Probes for non-invasive matrix metalloproteinase-targeted imaging with PET and SPECT. Curr. Pharm. Des. (2013) (Epub ahead of print